Key result
Surgical resection of primary cardiac sarcoma is linked to a median survival of 3.0 years.
Why the study?
The study was conducted to evaluate the outcomes of surgical resection of malignant primary cardiovascular tumors.
Cohort (n=32)
No
Surgical resection of primary cardiac sarcoma can be performed with zero operative mortality and provides a median survival of 3 years, though recurrence rates remain high and necessitate rigorous surveillance.
Supports resection consideration in primary cardiac sarcoma; leaves open optimal multimodality strategies and selection criteria.
Objective: To evaluate the outcomes of surgical resection of malignant primary cardiovascular tumors. Methods: From 1983 to 2018, 32 patients underwent surgical resection of malignant primary cardiovascular sarcoma at Cleveland Clinic. Mean age was 48 ± 15 years, and 19 (59%) were women. Outcomes are compared between those with complete resection and those without, and in relation to primary location. Results: The most common histologic subtypes were angiosarcoma (n = 8 [25%]) and high-grade undifferentiated sarcoma (n = 7 [22%]). Fourteen (44%) involved the left heart, 9 (28%) the right heart, 8 (25%) the pulmonary arteries, and 1 (3%) the aorta. There was clinical evidence of isolated extracardiac metastases in 8 (25%). Six (19%) patients were deemed unresectable at surgery, undergoing biopsy and palliative debulking followed by referral for definitive chemotherapy and/or radiation. The remaining 26 (81%) patients underwent 31 tumor resections with curative intent. Seven (22%) patients had previously undergone a resection or biopsy at another institution. There were 10 second-time resections, 2 third-time resections, 1 fourth-time resection, and no operative mortalities. Median survival was 3 years, with estimated survival at 6 months and 1, 5, and 10 years of 90%, 73%, 31%, and 17%, respectively. Of the 8 (25%) who were considered disease-free following surgery, 4 experienced recurrences during follow-up. Conclusions: Primary cardiac sarcoma continues to be a challenging disease with poor prognosis. Aggressive resection with curative intent, frequent surveillance for local and distant recurrence, and systemic and local multimodality treatment optimizes outcomes.
No takes yet. Share an insight, caveat, or question.
Hasan et al. (2021) conducted a cohort in Malignant primary cardiovascular sarcoma (n=32). Surgical resection was evaluated on All-cause mortality (median survival in years) (95% CI 1.08-4.7). Surgical resection of primary cardiac sarcoma resulted in a median survival of 3.0 years, with estimated survival at 1, 5, and 10 years of 73%, 31%, and 17%, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from JTCVS Open